1. Home
  2. ALNY

as 05-22-2024 4:00pm EST

$
-
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Founded: 2002 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 19.0B IPO Year: 2004
Target Price: $215.43 AVG Volume (30 days): 595.4K
Analyst Decision: Buy Number of Analysts: 16
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.67 EPS Growth: N/A
52 Week Low/High: $141.98 - $218.88 Next Earning Date: 05-02-2024
Revenue: $2,003,335,000 Revenue Growth: 75.20%
Revenue Growth (this year): 3.05% Revenue Growth (next year): 25.90%

Share on Social Networks:

Stock Insider Trading Activity of Alnylam Pharmaceuticals Inc. (ALNY)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
SHARP PHILLIP A ALNY Director Feb 29 '24 Sell $150.60 13,005 $1,958,553.00 16,995 SEC Form 4
SHARP PHILLIP A ALNY Director Feb 29 '24 Sell $151.43 13,557 $2,052,936.51 3,438 SEC Form 4
SHARP PHILLIP A ALNY Director Feb 29 '24 Sell $152.40 915 $139,446.00 2,523 SEC Form 4
SHARP PHILLIP A ALNY Director Feb 29 '24 Sell $153.62 1,906 $292,799.72 617 SEC Form 4
SHARP PHILLIP A ALNY Director Feb 29 '24 Sell $154.07 101 $15,561.07 516 SEC Form 4
SHARP PHILLIP A ALNY Director Feb 29 '24 Sell $156.54 516 $80,774.64 0 SEC Form 4
Greenstreet Yvonne ALNY Chief Executive Officer Feb 27 '24 Sell $154.54 1,259 $194,565.86 49,801 SEC Form 4
Greenstreet Yvonne ALNY Chief Executive Officer Feb 27 '24 Sell $155.45 993 $154,361.85 48,808 SEC Form 4
Greenstreet Yvonne ALNY Chief Executive Officer Feb 27 '24 Sell $156.38 588 $91,951.44 48,220 SEC Form 4
Greenstreet Yvonne ALNY Chief Executive Officer Feb 27 '24 Sell $157.30 84 $13,213.20 48,136 SEC Form 4
Greenstreet Yvonne ALNY Chief Executive Officer Feb 27 '24 Sell $158.09 8 $1,264.72 48,128 SEC Form 4
Franchini Indrani Lall ALNY EVP, CLO & Secretary Feb 27 '24 Sell $154.54 142 $21,944.68 4,320 SEC Form 4
Franchini Indrani Lall ALNY EVP, CLO & Secretary Feb 27 '24 Sell $155.45 111 $17,254.95 4,209 SEC Form 4
Franchini Indrani Lall ALNY EVP, CLO & Secretary Feb 27 '24 Sell $156.38 66 $10,321.08 4,143 SEC Form 4
Franchini Indrani Lall ALNY EVP, CLO & Secretary Feb 27 '24 Sell $157.30 9 $1,415.70 4,134 SEC Form 4
Franchini Indrani Lall ALNY EVP, CLO & Secretary Feb 27 '24 Sell $158.09 1 $158.09 4,133 SEC Form 4
Garg Pushkal ALNY CMO & EVP Dev & Med Affairs Feb 15 '24 Sell $147.50 480 $70,800.00 8,160 SEC Form 4
Garg Pushkal ALNY CMO & EVP Dev & Med Affairs Feb 15 '24 Sell $148.24 672 $99,617.28 7,488 SEC Form 4
Garg Pushkal ALNY CMO & EVP Dev & Med Affairs Feb 15 '24 Sell $149.03 156 $23,248.68 7,332 SEC Form 4
Tanguler Tolga ALNY EVP, Chief Commercial Officer Feb 15 '24 Sell $147.50 369 $54,427.50 4,710 SEC Form 4
Tanguler Tolga ALNY EVP, Chief Commercial Officer Feb 15 '24 Sell $148.24 519 $76,936.56 4,191 SEC Form 4
Tanguler Tolga ALNY EVP, Chief Commercial Officer Feb 15 '24 Sell $149.03 121 $18,032.63 4,070 SEC Form 4
Poulton Jeffrey V. ALNY EVP, Chief Financial Officer Feb 15 '24 Sell $147.50 369 $54,427.50 18,782 SEC Form 4
Poulton Jeffrey V. ALNY EVP, Chief Financial Officer Feb 15 '24 Sell $148.24 518 $76,788.32 18,264 SEC Form 4
Poulton Jeffrey V. ALNY EVP, Chief Financial Officer Feb 15 '24 Sell $149.03 120 $17,883.60 18,144 SEC Form 4